TF and neoplasm: Clinical benefit may be provided by direct blockade of PAR-1 or PAR-2 on tumor cells, inhibition of PAR-1 on platelets, fibroblasts, and ECs (ATAP2, WEDE15, SCH530348, SCH79797, vorapaxar), as well as administering inhibitors of thrombin (hirudin, argatroban), TF (TFPI, mAb-10H10), MMPs, and other serine protease inhbitors (serpins) [4, 5, 16, 22, 24, 87, 95, 96, 241, 242].